Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T CellsChien‐Hsing Chang, David M. Goldenberg, Yang Wang et al.|Cancer Research|2017Cited by 83
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancerThomas M. Cardillo, David M. Goldenberg, Diane L. Rossi et al.|Oncotarget|2020Cited by 56
Abstract 3193: Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51Thomas M. Cardillo, David M. Goldenberg, Ali Mostafa et al.|Cancer Research|2017Cited by 8
Figure S9 from Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T CellsChien‐Hsing Chang, David M. Goldenberg, Yang Wang et al.|Unknown|2023Cited by 0
Figure S10 from Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T CellsChien‐Hsing Chang, David M. Goldenberg, Yang Wang et al.|Unknown|2023Cited by 0